COVID-19：抗体カクテル療法が“予防薬”で承認：RONAPREVE（動画）：
COVID-19:Antibody cocktail therapy as a preventive drug: RONAPREVE
COVID-19：抗体鸡尾酒疗法被批准为“预防药物”：RONA PREVE
ー軽症患者向け「RONAPREVE」ー
「抗体カクテル療法」：
「抗体カクテル療法」は、新型コロナウイルスの軽症患者の治療に使われています。
厚生労働省の審議会：
無症状の人などを対象に、初めての「発症予防薬」としても使うことを了承しました。
軽症患者向け「RONAPREVE」：
審議会の特例承認が了承したのは、抗体カクテル療法に使用される中外製薬の「ロナプリーブ」です。
“コロナ予防薬”として承認
今年７月、重症化リスクのある軽症や中等症の患者の「治療薬」として特例承認されました。
新たに「発症の予防」を目的に加え、投与の対象が広がります。
中外製薬
臨床試験では、
家庭内濃厚接触者での発症リスクが、８１パーセント減りました。
検査では陽性で無症状の人で、発症するリスクが３１パーセント減少しました。
また、抗体カクテル療法は、点滴の形ですが、皮下注射も了承されました。
日テレNEWS24
https://www.news24.jp/articles/2021/11/04/07968978.html
Japan to use antibody cocktail to prevent symptoms
Japan’s health ministry
is to expand the use of a so-called antibody cocktail to prevent COVID-19 symptoms in patients’ families and others.
The ministry approved in July
the intravenous use of the antibody cocktail, which combines two types of antibodies, for patients with mild to moderate symptoms that could become severe.
Chugai Pharmaceutical,
the drug’s distributor in Japan,
had applied for expanding its use to include prevention.The company cited the results of overseas clinical trials
that show an 81 percent reduction in the risk of symptomatic coronavirus infections among people who were in close contact with infected family members.
On Thursday,
an expert panel approved the ministry’s policy to use the antibody cocktail for household exposure and asymptomatic cases.But it added that
the use in principle must be limited to those who are at risk of developing severe symptoms if infected.The panel stressed that
vaccination is the first line of defense for any infectious disease and limited the cocktail’s use to those who may not fully benefit from vaccination.It also agreed to subcutaneous administration, which takes less time than intravenous infusion.
The ministry is set to give formal approval on Friday,
after which the antibody cocktail will be the first drug approved in Japan to prevent COVID-19 symptoms.
NHK WORLD-JAPAN News